- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in drug major
Sun Pharma, Cassiopea Spa Ink License & Supply Agreements For Acne Treatment Drug Winlevi
The USFDA approved Winlevi (clascoterone cream 1 per cent) in August 2020, for the topical treatment of acne vulgaris in patients 12 years and older.
Read MoreCipla Gets USFDA Nod For Inhalation Product
Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Read MoreSun Pharma Settles Patent Litigation With Celgene Corporation For Cancer Drug Revlimid
Shares of Sun Pharma were trading 0.19 per cent lower at Rs 669.95 apiece on BSE.
Read MoreLupin Launches Digital Asthma Educator Platform
The new platform is the latest initiative under Lupin's long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments.
Read MoreLupin To Enter Digital Healthcare Space In India
Shares of Lupin Ltd were trading 0.29 per cent lower at Rs 1,243.30 apiece on BSE.
Read MoreSun Pharma Acquires Rights To Trademarks Of 3 Diabetes Drug Brands In India From AstraZeneca
AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for distribution of Dapagliflozin.
Read MoreSun Pharma Q4 Net Profit Zooms Over Two-Fold To Rs 894.15 Cr
Shares of Sun Pharmaceutical Industries closed at Rs 699.75 per scrip on BSE, down 0.55 per cent from its previous close.
Read MoreSun Pharma Recalls 50,868 Bottles Of Diabetes Drug In US
The US-based arm of the drug firm is recalling the affected lot of 500 mg tablets (in 500 count bottles) due to 'presence of foreign substance identified as activated carbon', as per the latest Enforcement Report issued by the US health regulator.
Read MoreCipla Launches RT-PCR Test Kit 'Viragen' In India Partnership With Ubio Biotech
Cipla will launch ViraGen test kit in the country in partnership with Ubio Biotechnology Systems
Read MoreNatco Seeks CDSCO Approval For Phase-III Trial Of Molnupiravir For COVID-19 Treatment
Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients
Read MoreDr Reddy's Receives DCGI Approval For COVID-19 Vaccine Sputnik For Restricted Emergency Use
Dr Reddy's had partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and distribute the vaccine in India.
Read MoreNatco Pharma Board Okays Acquiring 1% In Canadian Arm
Stocks of Natco Pharma were trading 0.74 per cent lower at Rs 810.85 apiece on BSE.
Read MoreWall Street Shifts Bets To Big Pharma As COVID-19 Vaccine Race Progresses
Companies including Pfizer and Johnson & Johnson have said they each aim to produce as many as 1 billion doses by the end of 2021.
Read More